Estimating the efficacy of isometric handgrip training to lower resting blood pressure in patients with stage 1 hypertension in Eastern Uganda compared to standard of care: study protocol for a randomized controlled trial Authors: Kate Zinszer, Henry Isabirye, Charles Kalumuna, Katia Charland, Agaba Katureebe, Margot Barbosa Da Torre, Paula M van Wyk, Stella Nabirye, Jessie Stone, Phillip Levy, Cheri McGowan Published: 2025 ABSTRACT AbstractBackgroundHypertension (HTN) is a major non-communicable disease worldwide, including in Uganda. Studies have estimated HTN prevalence in Uganda between 19 and 33% among adults, with only 7–9% controlled within clinical target ranges. Isometric handgrip training (IHT), a form of resistance training that consists of performing multiple static forearm contractions separated by brief rest periods on a handgrip dynamometer or stress ball, is a promising simple, time-efficient, and low-cost intervention. This randomized controlled trial (RCT) aims to determine the efficacy of 12 weeks of IHT compared to standard of care on resting blood pressure (BP) levels in a population of hypertensive patients at the Soft Power Mukagwa Allan Stone Community Health Clinic (Kyabirwa, Uganda).MethodsThis study consists of a two-arm, parallel, randomized controlled, superiority trial. Patients having (1) a diagnosis of stage 1 HTN (BP > 140–159/90–99 mmHg), (2) not currently taking HTN medication, (3) not having been on HTN medication in the past 3 months, and (4) aged ≥18 years will be recruited. A total of 250 participants will be randomized with equal allocation to intervention and control arms. The control arm will receive standard care for HTN for a duration of 12 weeks, as per clinic standard practice. In addition to standard care, the intervention arm will perform IHT sessions three times a week for a duration of 12 weeks. IHT sessions will consist of four 2-min isometric handgrip contractions, using alternate hands with 1-min rest periods between contractions (total: 12 min). The primary outcome is the mean resting systolic BP at 12 weeks. Data collection will be conducted at baseline, 1, 2, and 3 months and will include measurements of BP levels and administration of questionnaires.DiscussionThis RCT will provide evidence on the efficacy of IHT, a promising and cost-efficient therapy for blood pressure control in a Ugandan context. We anticipate that our results will inform treatment strategies for hypertensive patients in Uganda and in other high-burden LMIC contexts.Trial registrationRetrospectively registered. ISRCTN Registry; ISRCTN46005092; 31/10/2024.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13063-025-09258-y.Keywords: Hypertension, Isometric handgrip, Non-pharmaceutical intervention, Randomized controlled trial, Uganda Administrative information Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/). Title {1}Estimating the efficacy of isometric handgrip training to lower resting blood pressure in patients with stage 1 hypertension in Eastern Uganda compared to standard of care: study protocol for a randomized controlled trialTrial registration {2a and 2b}ISRCTN Registry; ISRCTN46005092 (https://doi.org/10.1186/ISRCTN46005092); 31/10/2024 (retrospectively registered)Protocol version {3}Protocol version 3.0, dated November 28, 2024Funding {4}Funding by the Canadian Institutes of Health Research (CIHR)Author details {5a}Kate Zinszer*1,2, Henry Isabirye3, Charles Kalumuna3, Katia Charland2, Agaba Katureebe3, Margot Barbosa Da Torre2, Paula M. van Wyk4,5, Stella Nabirye6, Jessie Stone3, Phillip Levy7, Cheri McGowan4,5,71Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, Canada2Research Center for Public Health, University of Montreal, Montreal, Canada3Soft Power Mukagwa Allan Stone Community Health Clinic, Kyabirwa, Uganda4Department of Kinesiology, University of Windsor, Windsor, Canada5WeSpark Health Institute, University of Windsor, Windsor, Canada6Cardiology Ward, Kiruddu Hospital, Kampala, Uganda7Wayne State University, Detroit, United States of America*Corresponding author (ORCID iD 0000-0003-1388-1145)Name and contact information for the trial sponsor {5b}Centre De Recherche en Santé Publique, Université de Montréal (cresp.ccsmtl@ssss.gouv.qc.ca)Role of sponsor {5c}Study sponsor and funder have no role in the design, execution, analyses, interpretation of the data, or decision to submit results Kate Zinszer*1,2, Henry Isabirye3, Charles Kalumuna3, Katia Charland2, Agaba Katureebe3, Margot Barbosa Da Torre2, Paula M. van Wyk4,5, Stella Nabirye6, Jessie Stone3, Phillip Levy7, Cheri McGowan4,5,7 1Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, Canada 2Research Center for Public Health, University of Montreal, Montreal, Canada 3Soft Power Mukagwa Allan Stone Community Health Clinic, Kyabirwa, Uganda 4Department of Kinesiology, University of Windsor, Windsor, Canada 5WeSpark Health Institute, University of Windsor, Windsor, Canada 6Cardiology Ward, Kiruddu Hospital, Kampala, Uganda 7Wayne State University, Detroit, United States of America *Corresponding author (ORCID iD 0000-0003-1388-1145) Introduction Background and rationale {6a} The global burden of hypertension (HTN) or high blood pressure (BP) ≥140/90 mmHg is distinctly skewed, with 75% of individuals diagnosed with HTN living in low- and middle-income countries (LMIC) [1–3]. Countries of sub-Saharan Africa, such as Uganda, have experienced the greatest increases in the absolute burden of HTN [3–6]. In Uganda, studies have estimated the prevalence of HTN to be between 19 and 33% among adults [5, 7–12] with only 7–9% of individuals controlled to within clinical target ranges with standard care [5, 12, 13]. Uncontrolled HTN substantially increases the risk for long-term and potentially fatal complications, including cardiovascular disease, renal failure, cognitive decline [14–18], and a poor quality of life [19]. With HTN being the leading cause of death and disability worldwide [20, 21] and an enormous contributor to the global burden of chronic non-communicable diseases [22], effective BP control is imperative. Cornerstones of HTN treatment such as health behavior, lifestyle management, and HTN pharmacotherapies have not been effectively administered in LMICs for reasons including healthcare system-, provider-, and/or patient-level barriers. These barriers include a lack of access to care, high provider burden, poor health care staffing, low patient health literacy, and lack of treatment adherence [4]. In Uganda, there are capacity gaps in human resources (e.g., trained clinical staff for HTN management) [23], equipment, drug supply, and laboratory capabilities [24], and less than 50% of health care facilities have guidelines for managing HTN [23]. Funding to support the program for the prevention and control of non-communicable diseases within the national MOH in Uganda is limited, and none of the publicly funded health facilities in Uganda meets the WHO standard for essential tools and medicines needed to implement effective interventions for non-communicable diseases [24, 25]. Furthermore, a study in Kampala, Uganda, reported that 80% of patients were non-adherent to their HTN medication [26]. High cost of HTN medications, long distances to healthcare facility, frequent stockout of medicines, fear of taking pills, and misinformation regarding herbal remedies and alternative treatments are all factors contributing to poor medication adherence [26, 27]. The limited accessibility of HTN medications combined with gaps in infrastructure, policies, and legislation severely impedes the effective prevention and management of HTN in Uganda [8, 23, 28]. IHT is a promising, simple, cost-effective, time-efficient, and highly tolerable intervention for managing HTN cited in clinical practice guidelines [29–35]. IHT is a form of resistance training comprised of multiple static forearm contractions separated by short rest periods performed on a portable handheld device, such as an inflatable stress ball. This therapy is recognized in the latest guidelines from the American College of Cardiology and the American Heart Association as one of the “Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension” [34]. Small-scale studies have shown that IHT reduces BP in both hypertensive and non-hypertensive populations globally, including individuals residing in LMICs and of African descent [36–45]. Additionally, pilot work from our team estimated that IHT lowered resting BP by an average of 7/2 mmHg in individuals of African descent with and without HTN [32, 37, 46]. Importantly, IHT is highly tolerable. Published studies have reported high rates of IHT compliance [31, 32, 36, 37], and findings from our pilot work indicated that patients with HTN also find IHT to be well-tolerated. Objectives {7} The primary objective of our study is to determine the efficacy of IHT in a population of HTN patients compared to standard care at the Soft Power Mukagwa Allan Stone Community Health Clinic in eastern Uganda. We will test the hypothesis that 12 weeks of IHT will produce statistically significant reductions in resting systolic BP when compared to standard care. Our secondary objectives include evaluating the effects of IHT on resting diastolic BP when compared to standard care after 12 weeks of IHT and comparing IHT on both systolic and diastolic BP at 1 and 2 months post-IHT in addition to safety outcomes and adherence to IHT. Trial design {8} We will conduct a two-arm, parallel, randomized controlled superiority trial to determine if there is a significant difference in resting BP after 12 weeks of IHT compared to standard care treatment for newly diagnosed HTN patients in a rural clinic in Eastern Uganda. There will be equal allocation of 125 participants to the intervention group (IHT and standard care) and to the control group (standard care only). Methods: participants, interventions, and outcomes Study setting {9} There is one center involved for this study, which is the Soft Power Mukagwa Allan Stone Community Health Clinic (SPH), Kyabirwa, Uganda. In 2024, the clinic provided medical consultations to 38,177 patients, with 7379 (21%) of these patients receiving treatment for HTN [47]. At the clinic, standard care HTN treatment is based on Ugandan MOH guidelines and involves health behavior and lifestyle guidance provided by clinic staff (e.g., increased aerobic exercise, weight management, optimization of diet, and limiting alcohol consumption) [48]. Participants will be selected among the SPH Clinic’s patients being treated for HTN or newly diagnosed with HTN. Eligibility criteria {10} Inclusion criteria are (1) diagnosis of stage 1 HTN (BP ≥ 140–159/90–99 mmHg [49, 50]), which is based on the clinic and MOH definitions [48], (2) not currently taking HTN medication, (3) not having been on HTN medication in the past 3 months, and (4) age ≥ 18 years. Exclusion criteria are (1) diagnosis of stage 1 HTN and currently taking HTN medication, (2) diagnosis of stage 2 HTN, (3) diabetes, (4) history of recent myocardial infarction (in the past year), (5) congestive heart failure, (6) complete heart block, (7) unstable angina, (8) glomerular filtration rate of 90 or lower, (9) any pregnancy-associated HTN, (10) any limitation (e.g., limited hand mobility) preventing proper performance of IHT exercise, and (11) any other condition that alters autonomic nervous system function. Who will take informed consent? {26a} All participants will provide signed informed consent before any study procedures are conducted, and ongoing consent will be confirmed during the monthly onsite visits. Consent forms will be provided by the research team to patients and will be translated into Lusoga—the local language. Participants will be given as much time as they need to read and comprehend the consent forms and will be able to ask questions to the researcher before they sign. Consent for access to hospital records during the study period will be obtained during the informed consent process. Additional consent provisions for collection and use of participant data and biological specimens {26b} Not applicable. No participant data and biological specimens will be collected and used in ancillary studies. Interventions Explanation for the choice of comparators {6b} Eligible and consenting patients will be randomized to either standard care for HTN (control group) or to the IHT intervention (intervention group). Participants in the control group will receive “standard care” for HTN as per clinic standard practice. In addition to receiving “standard care” for HTN, participants in the intervention group will perform IHT sessions three times a week for a duration of 12 weeks. Intervention description {11a} Standard care The standard of care/treatment of HTN at the clinic is based on Ugandan MOH clinical guidelines [48]. All HTN treatment at the clinic involves health behavior and lifestyle guidance provided by clinic staff (e.g., increased aerobic exercise, weight management, optimization of diet and limiting alcohol consumption, salt restriction) [48]. The health behavior and lifestyle guidance are the first line of treatment for patients with BP ≥ 140 mmHg/90 mmHg (stage 1 HTN) but below 160 mmHg/100 mmHg (stage 2 HTN). If there is no improvement after 3 months of follow-up with stage 1, drug therapy is initiated in combination with continued lifestyle and health behavior guidance. If there is no improvement after 1 month of drug therapy initiation, it is then classified as stage 2 HTN. The recommended drug therapies are calcium channel blockers as first-line treatment. Intervention: IHT The in-person IHT training sessions for the intervention group will be held at the SPH Clinic by research staff/trained nurses. Each training session will consist of 4, 2-min isometric handgrip contractions performed on an inflatable stress ball (Fig. 1) at a rating of perceived exertion of a 6 on a 10-point scale (equivalent to ~30% maximal voluntary contraction) [51, 52], using alternate hands with 1-min rest periods between contractions. Participants will attend 3 supervised group sessions per week. If participants are not able to attend the group sessions, participants will have the option to participate in an individual training session with research staff at another time during the week. Inflatable stress ball used for the IHT intervention (Sportime inflatable all-balls, reference #009532, [53]) Criteria for discontinuing or modifying allocated interventions {11b} Discontinuation will be considered for participants lost to follow-up or withdrawn from the study. In the event of participants missing 1 to 3 consecutive IHT sessions, additional IHT sessions will be scheduled for the following weeks (for a total of up to 5 sessions a week). If more than 3 consecutive sessions are missed, they will not be rescheduled the following week. All missed IHT sessions will be tracked. Strategies to improve adherence to interventions {11c} IHT sessions will be supervised by a trained research nurse to ensure appropriate execution of the intervention. Participation and follow-up will be encouraged by the research team and the flexibility of IHT sessions in terms of attending a group session or an individual session. Individual follow-ups and reminders will be done by phone before and/or after IHT sessions. Relevant concomitant care permitted or prohibited during the trial {11d} No concomitant care is prohibited during the trial. Medications taken by participants during the trial will be documented. Provisions for post-trial care {30} Participants from the intervention group will be given a stress ball at the end of their participation, to allow them to continue IHT training beyond the 12-week follow-up if they wish to. After completion of the study, control group participants will be provided with a stress ball and appropriate training and guidance from the research team to conduct IHT at home. Outcomes {12} Primary outcome The primary efficacy outcome measure is the mean resting systolic BP at week 12 (endline). BP assessments will be conducted by our medical research team members starting with baseline data collection and repeated monthly for the duration of the intervention (12 weeks). Secondary outcomes The secondary efficacy outcome measure is the mean resting diastolic BP from baseline to endline (week 12). Other secondary efficacy endpoints are systolic and diastolic BP from baseline at 4 and 8 weeks as well as time spent in a controlled to within clinical target ranges (≤139/89 mmHg). Resting BP will be measured at monthly clinic visits, to capture changes in systolic and diastolic BP, as well to identify severe (≥180/110 mmHg) HTN. The secondary efficacy outcome measure is the mean resting diastolic BP from baseline to endline (week 12). Other secondary efficacy endpoints are systolic and diastolic BP from baseline at 4 and 8 weeks as well as time spent in a controlled to within clinical target ranges (≤139/89 mmHg). Resting BP will be measured at monthly clinic visits, to capture changes in systolic and diastolic BP, as well to identify severe (≥180/110 mmHg) HTN. The need for HTN medication at endline, as per clinical and MOH guidelines, which will be measured through changes in BP levels at endline (week 12). The need for HTN medication at endline, as per clinical and MOH guidelines, which will be measured through changes in BP levels at endline (week 12). Safety outcomes include the following events: hospital admission for hypertensive crisis, severe (≥180/110 mmHg), new myocardial infarction, transient ischemic attack, and new embolic event, which will be assessed at 4, 8, and 12 weeks (endline) after randomization. This information will be captured by the questionnaire and by clinic and hospital records. Safety outcomes include the following events: hospital admission for hypertensive crisis, severe (≥180/110 mmHg), new myocardial infarction, transient ischemic attack, and new embolic event, which will be assessed at 4, 8, and 12 weeks (endline) after randomization. This information will be captured by the questionnaire and by clinic and hospital records. Intervention and control group adherence will also be measured as a secondary outcome and will be captured based on IHT attendance and clinic visits throughout the follow-up period for those in the intervention arm and monthly clinic visits for those in the control arm. The number of missed IHT sessions and clinic visits will be counted, and the reasons for non-adherence will be documented. Intervention and control group adherence will also be measured as a secondary outcome and will be captured based on IHT attendance and clinic visits throughout the follow-up period for those in the intervention arm and monthly clinic visits for those in the control arm. The number of missed IHT sessions and clinic visits will be counted, and the reasons for non-adherence will be documented. HTN medication adherence for those prescribed HTM medication during their follow-up which will be measured through self-report and pill counting (counting the remaining pills for prescribed medication). Participants will be requested to bring their medication to each clinic visit. HTN medication adherence for those prescribed HTM medication during their follow-up which will be measured through self-report and pill counting (counting the remaining pills for prescribed medication). Participants will be requested to bring their medication to each clinic visit. Sociodemographic, lifestyle, and general health information will be measured as a secondary outcome and will be captured by a questionnaire at baseline (week 0). Changes in lifestyle and general health information will be captured with a shortened version of the baseline questionnaire at 4, 8, and 12 weeks (endline). Questionnaires will be administered by research staff. Sociodemographic, lifestyle, and general health information will be measured as a secondary outcome and will be captured by a questionnaire at baseline (week 0). Changes in lifestyle and general health information will be captured with a shortened version of the baseline questionnaire at 4, 8, and 12 weeks (endline). Questionnaires will be administered by research staff. Knowledge about HTN and experience with IHT (if applicable) will also be captured as a secondary outcome using additional questions in the baseline and the endline (week 12) questionnaires. Knowledge about HTN and experience with IHT (if applicable) will also be captured as a secondary outcome using additional questions in the baseline and the endline (week 12) questionnaires. Participant timeline {13} The duration of follow-up will be 12 weeks, from baseline collection to the end of the 12 weeks of the intervention (Fig. 2). BP testing will occur at baseline (week 0) and will be repeated monthly for the duration of the intervention in the clinic (weeks 4, 8, and 12). During the baseline visit (week 0), a short questionnaire will also be administered by a study nurse to capture information about sociodemographics, lifestyle, and health information. Changes in lifestyle and health information will be captured by a shortened version of the baseline questionnaire during the monthly follow-up visits (weeks 4, 8, and 12). A questionnaire capturing HTN knowledge and experience of IHT handgrip session (if applicable) will be administered at baseline (week 0) and at endline (week 12). Overview of the enrollment, intervention, and assessment as per the Standard Protocol Items Recommendations for Intervention Trials (SPIRIT) Statement Sample size {14} The sample size was determined based on statistical power analyses for our primary hypothesis and analysis by ANCOVA with baseline systolic blood pressure as the covariate. We estimate a conservative sample size on the equivalent analysis without covariates, the two-sample t-test. Assuming a common standard deviation of 10 mmHg and an alpha level of 0.05, 100 patients per group will provide 80% power to detect a clinically meaningful 4 mm Hg difference [36] in mean change in systolic BP from baseline to week 12 between the IHT group and the standard care group. Based on our pilot study, which included 16 weeks of IHT, we experienced an 18% loss to follow-up. Given this, we anticipate a 20% loss to follow-up for this study, which then requires 125 per group and 250 participants in total. Recruitment {15} There were 7379 (21%) patients at the clinic who were treated for HTN in 2024 [47]. Based on clinic data, of those HTN patients treated in 2024, approximately 30% were newly diagnosed HTN, with the vast majority being identified as stage 1 HTN (inclusion criteria). Based on current numbers, we anticipate that there will be 10–15 patients per day that meet our eligibility criteria. With our 85% response rate that was obtained in the pilot study, we should be able to realistically recruit 50 participants per week. To avoid clinic overburden, blocks of 50 participants will be enrolled at a time, and recruitment of these participants will be conducted over a 2-week period, followed by the 12 weeks of follow-up and a final 2-week period to complete the remaining activities for a total of 16 weeks. In total, 5 blocks of 16 weeks will be repeated over the 2-year period. All clinicians at SPH will be made aware of the study and the eligibility criteria for participants during a staff meeting and study materials. The potential participants will be identified during their routine visits to the clinic, based on the eligibility criteria. If eligible, a clinician will introduce the potential participant to the research coordinator, who will explain the study to the patient and review the consent form orally, which provides the study objectives, the role of participants, and the information that will be recorded during observations. They will also explain and demonstrate the IHT protocol to the patient. If the patient is interested in participating, informed written consent will be obtained. Consented participants will then be allocated to the intervention or control group. The baseline questionnaire and a baseline measure of blood pressure will be obtained by a study nurse according to clinic standard practice during the baseline visit (week 0). Assignment of interventions: allocation Sequence generation {16a} Participants will be randomized with equal allocation to intervention and control groups. A computer-generated randomization will be used for random permuted blocks of different sizes to allocate participants to either of the arms. Randomization will be stratified by baseline systolic blood pressure level (140–149 mmHg vs. 150–159 mmHg) as baseline BP is a prognostic factor of our primary outcome: the mean systolic BP at 12 weeks. This will be accompanied by adjustment for baseline BP in the analysis as well as adjusting for HTN medication. Given the modest sample size, stratification will help protect against bias from imbalance on HTN stage. Concealment mechanism {16b} After obtaining baseline data from all participating individuals in the 50-participant block, the research coordinator will log into REDCap and receive the random assignment for the participant. The randomization sequence and block sizes used to allocate participants to the study arms will be concealed from study personnel. Implementation {16c} Enrollment of participants and implementation of the allocated intervention will be conducted by the research coordinator. All randomization procedures will be conducted by a biostatistician not associated with the study. Assignment of interventions: blinding Who will be blinded {17a} Due to the nature of the intervention, neither participants nor research team members involved with IHT sessions and data collection (e.g., questionnaire, BP measurement) can be blinded to treatment allocation. All other research personnel involved in data analyses will be blinded. Procedure for unblinding if needed {17b} Not applicable. Participants and research team members involved in the intervention and data collection will not be blinded. Data collection and management Plans for assessment and collection of outcomes {18a} Standard operating procedures (SOPs) will be implemented for all procedures included in the study (e.g., questionnaire administration, IHT sessions, BP measurement). All research members and personnel will adhere to strict data quality assurance processes. A training session prior to study commencement will be held for all research team members to ensure good practices during data collection. The procedures’ stringent application will be supervised by the research coordinator. Blood pressure Resting BP will be assessed in the right upper arm at baseline and at each monthly clinic visit (weeks 4, 8, and 12), using the validated automated Omron HEM-907XL (eligibility and testing) device after 5 min of seated rest. A series of three readings will be taken and recorded, and the average measure will be used for the outcome [54, 55]. All participants will be tested in the morning under standard conditions (e.g., 12-h post-caffeine, 4-h post-prandial, voided bladder, 24-h post-exercise (including IHT)) with repeat testing occurring within 2 h of the initial baseline time. The measures will be recorded on paper and then entered into REDCap via the participant’s study code. Questionnaire Participants will be asked to complete a questionnaire at each clinic visit. Questionnaires will be administered by a study nurse and will be paper-based, with the data entry and storage to occur with REDCap. The written questionnaires will be translated into Lusoga and will be read aloud for patients who are not able to read. The baseline questionnaire, administered at the beginning of the study (week 0), will ask open and closed questions on sociodemographic, lifestyle, and health information. The questionnaire will take approximately 5–10 min to complete. A modified version of the baseline questionnaire will be used for subsequent times to capture any changes in the information previously collected. This follow-up questionnaire, administered at the monthly clinic visit 1 (week 4), 2 (week 8), and endline (week 12), will take approximately 5–10 min to complete. To capture knowledge about HTN and experience of IHT (if applicable), additional questions will be included in the questionnaire at baseline (week 0) and endline (week 12). These additional questions will take approximately 5 min to complete. Hospital and clinic records Consent to access participants’ SPH Clinic records and hospital records will be obtained, and these data will be used to obtain safety outcome measures such as hospital admission for hypertensive crisis, severe (≥180/110 mmHg) and persistent hypertension (BP ≥ 175/105 mmHg), new myocardial infarction, new stroke, and new embolic event. A data extraction form will be developed, and the information will be entered into REDCap. Medication adherence All types of medication, including HTN medication, taken by participants will be tracked through the questionnaires (i.e., self-reporting) and clinic records. Participants who are prescribed HTN medication during their follow-up will also be requested to bring their medication at each clinic visit for pill counting (counting the remaining pills for prescribed medication). All information will be tracked and entered into REDCap. IHT session attendance Adherence of participants will be captured based on their attendance at IHT training sessions (intervention participants) and clinic visits (control and intervention participants). The number of missed IHT sessions and clinic visits will be counted, and the reasons for non-adherence will be documented. A chart will be used to track attendance, and attendance will be entered into REDCap. Plans to promote participant retention and complete follow-up {18b} Monthly clinic visits will be scheduled in accordance with the participant’s availability, and personalized reminders will be sent to participants. Participants will receive compensation for transportation to and from the clinic for each IHT session and for the monthly clinic visits. If participants develop the need for HTN medication based on clinical guidelines, the cost of HTN medication will be covered for the duration of their participation. Data management {19} Data management procedures will strictly follow the study SOPs. All personal information collected during the completion of the consent form as well as the answers to the questionnaires will remain confidential. The consent form will contain the names of the participants, but a study code will be used to link the questionnaire and data to each participant. Access to personal identifiers will be strictly restricted to the research personnel involved in the intervention and data collection. Internal monitoring (e.g., data entry in the REDCap database, informed consent documentation, eligibility criteria, randomization) will be overseen by the trial coordinator. A weekly monitoring of the REDCap database will be conducted by a member of the research team not involved in the data collection to ensure good data quality. Any errors or missing data information will be reported to the trial coordinator to verify the original records/questionnaires and make the necessary corrections. All errors, missing data, and corrections will be tracked. Confidentiality {27} All records that contain names or other personal identifiers will be stored separately and will have restricted access: paper informed consent forms will be stored under lock and key at the clinic and coded IDs will be filed in a password-protected REDCap database. The research records from which the data has been obtained will be securely stored at the research site for at least 5 years after completion of the research project. Anonymized data will be securely stored on a secured One Drive cloud following Canadian and Ugandan access to information and privacy laws. The electronic data will be kept for as long as it is needed following the completion of the study, when it is removed from the cloud. Only members of the research team will have access to the cleaned final datasets. Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in this trial/future use {33} Not applicable. No biological specimens will be collected. Statistical methods Statistical methods for primary and secondary outcomes {20a} The analysis will occur at the end of the data collection period. We will follow an intention-to-treat (ITT) approach. Descriptive statistics by intervention group at each 4-week interval will be presented for primary, safety, and secondary outcomes, where appropriate; counts and relative frequencies for categorical variables and means, standard deviations (and/or medians and interquartile ranges) for continuous outcomes. For the primary efficacy endpoint, we will use an ANCOVA with systolic BP at 12 weeks as the outcome, intervention group as the explanatory variable, and adjustment for baseline systolic blood pressure. We will adjust for baseline systolic BP as it is considered an important prognostic factor, and randomization was stratified by baseline systolic BP level. The relationship between the outcome and baseline BP will be modeled as a linear term, but we will assess any gains in precision by modeling baseline BP as a restricted cubic spline with three knots. A sensitivity analysis will adjust for additional potential prognostic factors measured at baseline. These factors are age group, sex, and HTN medication use (any/none). Due to the modest sample size, random effects will be used to control for each stratum of age group, sex, and HTN medication use. A third sensitivity analysis will further adjust the main analysis and sensitivity analysis for the interaction of baseline systolic BP and intervention group [56]. For the secondary endpoint of adherence (scale of 1 to 100), we will use mixed models for repeated measures (MMRM) with an unstructured covariance matrix, with fixed effects for time and intervention group and time by intervention interactions, adjusting for HTN stage, safety events, and participant sociodemographics. Similarly, the repeated systolic and diastolic BP outcomes will be analyzed by an MMRM with an unstructured covariance matrix, with fixed effects for time, intervention group and time by intervention interactions, baseline medication use (any/none), age group, and sex. All 4 time points will be included in this analysis (baseline, 4-, 8-, and 12-week follow-up) to improve the precision of estimates and support valid inference under the missing-at-random assumption. The safety outcomes either related or unrelated to the intervention (hypertensive crisis, severe and persistent hypertension [BP > 175/105 mmHg], new myocardial infarction, new stroke, and new embolic event) will be presented descriptively and will be analyzed by logistic regression of any event vs. none, with intervention group as the explanatory variable and adjusting for baseline blood pressure, age group, sex, and baseline medication use. Interim analyses {21b} Not applicable. No interim analyses will be conducted. Methods for additional analyses (e.g., subgroup analyses) {20b} Subgroup analyses We will conduct exploratory subgroup analyses for HTN medication use (any vs. none), for age group, and for sex. This will be done in three ways. In the first approach, we will include an interaction term between intervention group and HTN medication use in the ANCOVA analysis of 12-week systolic blood pressure. Interactions will be similarly assessed for intervention and age group, and intervention and sex. In the second approach, we will stratify the models for 12-week systolic BP by HTN medication use group, then separately by age group and then by sex. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c} If there is loss to follow-up, we will re-run the main analysis and sensitivity analyses using inverse probability of censoring weights to mitigate any selection bias. For missing baseline covariate data, multivariate imputation by chained equations will be used under the missing at random assumption. Plans to give access to the full protocol, participant-level data, and statistical code {31c} Anonymized data and statistical code generated by this study will be available upon reasonable request to the corresponding author, once the data on the study outcomes have been published. Oversight and monitoring Composition of the coordinating center and trial steering committee {5d} On-site management HI from the SPH Clinic will manage and oversee the administrative and day-to-day operations of the trial. AK, a Ugandan research coordinator who has experience in clinical trial management, will be responsible for coordinating medical research team members, as well as the development and implementation of SOPs, and data entry. Three study nurses will recruit participants, obtain informed consent, conduct observed IHT training, and collect data during the baseline and monthly clinic visits with a clinic physician. Monthly reports will be provided to the trial steering committee. A workshop will be held at the beginning of the study for research team members, and regular research team meetings will be held to ensure project progress and team-based solutions to the different challenges. Research team members will respect Canadian and Ugandan codes of ethical research practice. Trial steering committee The Steering Committee is composed of internal members of the study team. This committee will manage the overall conduct of the study and meet monthly to monitor study progress and address issues. The committee will be responsible for study design, execution, analysis, and determining if the safety outcomes are related to the intervention. Composition of the data monitoring committee, its role and reporting structure {21a} Given the low risk of the intervention, there will not be an external data safety and monitoring committee. The trial steering committee overseeing the overall study will manage procedure and data monitoring and also address data quality issues. Adverse event reporting and harms {22} IHT is a safe intervention for adults with HTN [57]. The research team will review monthly BP readings for all participants. For participants that have BP ≥ 175/105 mmHg, near the threshold of severe HTN (≥180/110 mmHg), they will be asked to return to the clinic within 72 h for re-assessment by members of the clinic’s medical team. If BP persists at ≥175/105 mmHg, participants will be excluded for safety and treated as per standard clinic procedures. These procedures include screening for comorbidities including diabetes, renal function tests, re-evaluating their hypertensive medication and schedule, and increasing the frequency of visits to every 2 weeks until their BP is stabilized. Participants may also experience numbness and/or tingling in the arm while their blood pressure is being measured. Participants randomized to IHT may experience tendonitis in their arms from the handgrip exercise; however, this risk is low if the exercise is properly performed. To avoid tendonitis among participants, IHT sessions will be completed under the supervision of research personnel to ensure proper exercise technique throughout the 12 weeks of the intervention. This will also allow the close monitoring of any safety events (hospital admission for hypertensive crisis, severe hypertension (BP ≥ 180/110 mmHg), new myocardial infarction, new stroke, and new embolic event), which will be identified to be related or unrelated to the trial via consultation with medical research team members, and appropriately reported. Any serious safety events determined to be related to IHT will be reported to the research ethics boards. Other safety events that may be associated with the care of HTN patients will be monitored. These may include adverse drug reactions (ADRs). Common ADRs: dizziness, headaches, fatigue, cough (especially with ACE inhibitors), and gastrointestinal disturbances. Common ADRs: dizziness, headaches, fatigue, cough (especially with ACE inhibitors), and gastrointestinal disturbances. Serious ADRs: angioedema, severe hypotension, renal impairment, hyperkalemia, and allergic reactions. Serious ADRs: angioedema, severe hypotension, renal impairment, hyperkalemia, and allergic reactions. Frequency and plans for auditing trial conduct {23} Weekly study management-related meetings and monthly steering committee meetings will be conducted to monitor study execution and safety issues. Plans for communicating important protocol amendments to relevant parties (e.g., trial participants, ethical committees) {25} Important protocol amendments will be reported to the different research ethics boards (i.e., Université de Montréal, Uganda National Council for Science and Technology, Mbarara University, University of Windsor), study participants, and trial registry. Dissemination plans {31a} Knowledge translation and exchange will be a central activity of the project. Our key activities will include (1) presenting results to study participants and community leaders, (2) presenting results to local (e.g., SPH Clinic, Jinja Regional Referral Hospital) and national knowledge users (e.g., MOH) and researchers (e.g., Makerere University), (3) presenting results at regional and international scientific meetings including associations that produce hypertensive care guidance and guideline documents (Uganda Heart Association, Pan-African Society of Cardiology, American Heart Association, Canadian Congress of Cardiology, International Society of Hypertension Scientific Meeting), (4) online dissemination of the results to the public via the study website and social media (e.g., Twitter, Facebook), and (5) educational webinars for result dissemination and to demonstrate IHT. We will use a variety of methods for dissemination, including infographics, research snapshots, videos, and policy briefs. We will also disseminate the results to the broader scientific community through publications in international journals (Hypertension, Journal of Hypertension) and regional journals (Cardiovascular Journal of Africa) with open access options. Discussion This study will provide important insight into the efficacy of a promising, cost-efficient therapy endorsed by the American and Australian Colleges of Cardiology as well as the American Heart Association as a BP-lowering treatment [34, 58]. This study will offer insight into IHT as a HTN management tool in clinical practice in a rural eastern African context. Our partnership with SPH, Makerere University, and the Ministry of Health in Uganda ensures active collaboration, relevant research and approaches, and effective knowledge transfer and exchange. Prior to this RCT, we conducted a pilot study at the clinic to test study methods and instruments which informed participant recruitment and our approach to participant compensation. Building on insights from the pilot, we determined that conducting in-clinic IHT sessions is essential to maximize participant adherence. However, our in-clinic approach of delivering IHT is not sustainable for larger studies due to the significant resources it demands for clinic staff and participants. The future phase of our research will aim to address this limitation by developing a more practical and scalable model to deliver IHT. Our next step will then be to conduct a multi-site pragmatic trial within Uganda to determine the effectiveness of IHT in the real-life Ugandan context. The longer-term goal of this work is to help inform develop evidence-based HTN management in Uganda as well as in other high-burden LMIC contexts. Patient and public involvement Patient or public will not be involved in the design, conduct, and reporting of the trial. Trial status Protocol version 3.0, November 28, 2024. Recruitment start date: 26/08/2024. Anticipated completion of recruitment: 02/02/2026. Supplementary Information Additional file 1. SPIRIT checklist. Acknowledgements We acknowledge and thank our study nurses: Andrew Mwesigwa, Margret Nantume, Rebecca Yandaga; all SPH staff for their involvement in participant recruitment; Hannah Fromont for her administrative and logistical support; Cora Siebert and all other research team members for helping develop this study; Sarah Vahey and Claudia Ximena Robayo Gonzalez for the randomization preparation and implementation; and all current and future research participants for their involvement in this study. Abbreviations Adverse drug reactions Blood pressure Hypertension Isometric handgrip training Intention-to-treat Low- and middle-income countries Ministry of Health Randomized controlled trial Standard operating procedures Soft Power Mukagwa Allan Stone Community Health Clinic Authors’ contributions {31b} KZ, HI, and CM are the principal investigators. KZ, HI, CK, KC, PMvW, SN, JS, PL, and CM conceived the study and protocol development. AK and MBDT contributed to study design and to the development of the protocol and are study coordinators. All authors read and approved the final manuscript. Funding {4} The Canadian Institutes of Health Research provided funding through the Project Grant program (PJT-190314). The funder had no role in the design of the study and will not have a role in data collection, analyses, interpretation of the data, writing of manuscripts, and dissemination of findings. Data availability {29} Members of the research team will have access to the cleaned final datasets. The final anonymized dataset will be made available after the publication of the study outcomes, if the participants have consented and upon reasonable request to the corresponding author. Declarations Ethics approval and consent to participate {24} Ethic approvals were sought at the Clinical Research Ethics Committee of the University of Montreal (approved 19/06/2024, ref: 2024-5649); at the Mbarara University of Science and Technology Research Ethics Committee (approved 27/07/2024, ref: MUST-2024-1547); at the Uganda National Council for Science and Technology (approved 22/08/2024, ref: HS4712ES); and at the University of Windsor Research Ethics Board (approved 06/10/2024, ref: 24-165). Written, informed consent to participate will be obtained from all participants. Consent for publication {32} Not applicable. Competing interests {28} The authors declare that they have no competing interests. Footnotes Publisher’ s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Additional file 1. SPIRIT checklist. Data Availability Statement Members of the research team will have access to the cleaned final datasets. The final anonymized dataset will be made available after the publication of the study outcomes, if the participants have consented and upon reasonable request to the corresponding author.